France Oligonucleotide Synthesis Market Size & Outlook
The oligonucleotide synthesis market in France is expected to reach a projected revenue of US$ 388.0 million by 2033. A compound annual growth rate of 14% is expected of France oligonucleotide synthesis market from 2026 to 2033.
Thermo Fisher Scientific Inc, Merck KGaA, GE HealthCare Technologies Inc Common Stock, Agilent Technologies, Kaneka Corp, Heritage Global Inc, Twist Bioscience Corp, Bio-Synthesis, Biolegio
Other key industry trends
In terms of revenue, France accounted for 3.8% of the global oligonucleotide synthesis market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany oligonucleotide synthesis market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 708.0 million by 2033.
The burden of cancer is significant in France, with cancer being the leading cause of death. Oligonucleotides are increasingly important in cancer diagnostics, including personalized medicine approaches, such as gene expression profiling and liquid biopsies.
They also hold promise for developing novel anticancer therapies like RNA interference (RNAi) drugs. Moreover, cardiovascular diseases are another major health concern in France, and oligonucleotides are being investigated for their potential in diagnosing & treating conditions like atherosclerosis and heart failure.
Furthermore, the geriatric population is increasing in France, leading to a rise in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. Oligonucleotides are diagnostic tools and therapeutic interventions for these debilitating conditions.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oligonucleotide Synthesis Market Outlook will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 43.31% in 2025.
Horizon Databook has segmented the France oligonucleotide synthesis market based on oligonucleotides, equipment/synthesizer, reagents, services covering the revenue growth of each sub-segment from 2021 to 2033.
The burden of cancer is significant in France, with cancer being the leading cause of death. Oligonucleotides are increasingly important in cancer diagnostics, including personalized medicine approaches, such as gene expression profiling and liquid biopsies.
They also hold promise for developing novel anticancer therapies like RNA interference (RNAi) drugs. Moreover, cardiovascular diseases are another major health concern in France, and oligonucleotides are being investigated for their potential in diagnosing & treating conditions like atherosclerosis and heart failure.
Furthermore, the geriatric population is increasing in France, leading to a rise in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. Oligonucleotides are diagnostic tools and therapeutic interventions for these debilitating conditions.
France Oligonucleotide Synthesis Market Product Outlook (Revenue, USD Million , 2021-2033)
Oligonucleotides
Equipment/Synthesizer
Reagents
Services
France Oligonucleotide Synthesis Market Application Outlook (Revenue, USD Million , 2021-2033)
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In Situ Hybridization (FISH)
Antisense Oligonucleotides
Other Applications
France Oligonucleotide Synthesis Market End Use Outlook (Revenue, USD Million , 2021-2033)
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Reasons to subscribe to Oligonucleotide Synthesis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Oligonucleotide Synthesis Market Outlook databook
Our clientele includes a mix of Oligonucleotide Synthesis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Oligonucleotide Synthesis Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Oligonucleotide Synthesis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Oligonucleotide Synthesis Market, 2021-2033 (US$M)